Amaia Lujambio Goizueta, PhD, discusses mutations commonly seen in hepatocellular carcinoma, and the targeted therapies available for these tumors.
Amaia Lujambio Goizueta, PhD, an assistant professor of Oncological Sciences at the Icahn School of Medicine at Mount Sinai, discusses mutations commonly seen in hepatocellular carcinoma (HCC), and the targeted therapies available for these tumors.
0:08 | Every tumor is very diverse in every tumor type, but HCC is in particular very diverse if we compare it to other tumor types. That means that tumors from different patients have very different mutations and very different combinations of mutations.
0:28 | So, the gene that is most frequently mutated is the promoter of a telomerase, which confers the cancer cells with basically unlimited replication potential. And then there are other genes such as p53, and beta catenin that are also frequently mutated. However, the way these mutations are mutated, they are not mutated together. They are mutated in different patients. So, that makes it more difficult to treat because right now, there are not selective therapies for HCC patients, which means that basically, all the patients receive the same treatment more or less. There are different therapies but there is not a way of selecting the best therapy for each patient.
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More
Gholam Analyzes Treatment Outcomes for Advanced HCC in Child-Pugh B Population
April 28th 2024During a live Community Case Forum event in partnership with the Tennessee Oncology Practice Society, Pierre Gholam, MD, examined the current state of treatment for patients with hepatocellular carcinoma, looking in particular at what data is available for those with Child-Pugh B and C status who have poorer outcomes and have limited data from prospective clinical trials.
Read More